CSL shares (ASX:CSL) experienced a dramatic sell-off today, plummeting 16.9% to A$225.50. This marks the stock’s lowest level in years, and comes as the company released FY25 results that on first glance were not all that bad. Looking a little deeper, and it becomes clear that a planned spinoff has not gone down well with markets.
The biopharmaceutical giant announced a 5% increase in revenue to US$15.6 billion and a 17% jump in net profit after tax (NPAT) to US$3.0 billion. Despite these positive figures, markets appear to be focusing on strategic shifts and as usual, future growth prospects.
Slowing growth momentum in key segments and uncertainty surrounding the planned demerger of CSL Seqirus have not helped sentiment, whilst the broader market volatility may also be contributing to the scale of the pullback.
CSL’s FY25 performance included an 11% increase in earnings before interest, tax, depreciation, and amortisation (EBITDA) to US$5.3 billion. The company also increased its final dividend by 12% to US$1.62 per share. Cash flow from operations saw a substantial 29% increase, reaching US$3.6 billion.
Operationally, CSL Behring continued to be a strong performer, driven by demand for immunoglobulin and haemophilia products. CSL Vifor posted an 8% revenue increase, supported by its iron and nephrology portfolios. CSL Seqirus maintained its market leadership in influenza vaccines, securing significant avian flu contracts.
Top Australian Brokers
- Pepperstone - Top Australian broker - Read our review
- eToro - Invest in ASX and international shares - Read our review
However, CSL’s strategic announcements have overshadowed these positive results. The company plans to demerge CSL Seqirus as a separate ASX-listed entity in FY26. Furthermore, CSL intends to restart a multi-year on-market share buyback program from FY26, with an initial A$750 million allocated for the first year.
Looking ahead, CSL anticipates group revenue growth of 4–5% in FY26. The company also expects annual pre-tax cost savings exceeding US$500 million by FY28, which will be reinvested into priority growth areas.
While the market reacted negatively to the news, there is a possibility that the scale of the sell-off is an overreaction. The demerger of Seqirus could unlock significant value by allowing both entities to focus on their core competencies. CSL Behring’s robust performance in plasma therapies remains a solid foundation for future growth.
Furthermore, the planned share buyback could provide support for the share price in the medium term.
Analysts are currently assessing the impact of the Seqirus demerger and the overall restructuring plans. Some have expressed concerns about the company’s ability to meet its ambitious targets, particularly given the challenges facing Seqirus and ongoing integration concerns with Vifor.
The upcoming months will be crucial for CSL as it executes its strategic plans and navigates the challenges in the global healthcare market. The company’s ability to deliver on its cost-saving targets and drive growth in key segments will be critical in restoring market confidence.
Don’t Buy Just Yet
You will want to see this before you make any decisions.
Before you decide which shares to add to your portfolio you might want to take a look at this special report we recently published.
Our experts picked out The 5 best ASX shares to buy in 2025.
We’re giving away this valuable research for FREE.
Click below to secure your copy
